Rather than supplying additional precursors, it limits NAD+ depletion by inhibiting NNMT, allowing exploration of upstream metabolic control
The Audit Verdict BPC-157 is a legitimate research compound in the specific sense that it has an established molecular identity (sequence GEPPPGKPADDAGLV, MW 1419.5 Da [1] ), a reproducible synthetic production pathway, and a substantial peer-reviewed animal research literature published in indexed journals [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14]
By months four through six, the medication has generally reached its target dose and patients are experiencing its full metabolic effect
Torres-Ruiz J, Absaln-Aguilar A, Nuez-Aguirre M et al (2021) Neutrophil Extracellular Traps Contribute to COVID-19 Hyperinflammation and Humoral Autoimmunity
+ - 5-Amino-1-methylquinolinium iodide, commonly referred to as 5Amino1mq, functions as a potent selective small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor in preclinical biological research